Provigil Cost in Illinois 2026: Prices, Insurance, Medicaid and Compounding

What Is Provigil and Why Does the Price Vary So Much in Illinois?

Modafinil (brand name Provigil, manufactured by Cephalon) is a Schedule IV wakefulness-promoting agent approved by the FDA for narcolepsy, obstructive sleep apnea with residual sleepiness, and shift-work sleep disorder. [1] Price variation in Illinois comes from a collision of list pricing, pharmacy markup, insurance tiers, and the existence of both generic and compounded alternatives. Brand Provigil carries a list price near $850 per month. Generic modafinil, produced by multiple manufacturers since patent expiration, averages roughly $80 per month at Illinois retail pharmacies in 2026 on a cash basis.

The drug's Schedule IV classification under the Controlled Substances Act means Illinois pharmacies must follow state-level record-keeping requirements, which adds a small layer of operational cost but does not meaningfully affect retail price. [2] The DEA registration requirements for dispensing Schedule IV medications are codified in 21 CFR Part 1304. [2]

Modafinil's mechanism differs from amphetamines. The exact pathway is not fully characterized, but modafinil appears to inhibit dopamine reuptake through the dopamine transporter, raising extracellular dopamine without triggering the broad monoamine release seen with amphetamine. [3] That pharmacological profile is part of why clinicians consider it a lower-abuse-risk option than Schedule II stimulants, and why Illinois Medicaid treats it as a coverable drug rather than an automatic exclusion.

In the 1998 US Modafinil in Narcolepsy Multicenter Study (N=271, published in Annals of Neurology), modafinil 200 mg and 400 mg produced statistically significant reductions in Epworth Sleepiness Scale scores versus placebo (P<0.001), establishing the clinical evidence base that supports its continued prescription today. [4]

Provigil Cash Prices at Illinois Pharmacies in 2026

Generic modafinil averages $80 per month at Illinois retail pharmacies, a figure that varies by chain, geography, and pill count. Brand Provigil at the same pharmacies will run $800 to $900 per month without any discount card or coupon applied.

Prices differ meaningfully by location within Illinois. Urban pharmacies in Chicago and its suburbs often have more competitive pricing due to volume, while rural downstate pharmacies may price generics $10 to $25 higher per month. The table below reflects approximate 2026 cash prices for 30 tablets of modafinil 200 mg at major Illinois chains without discount programs applied.

Independent pharmacies enrolled in GoodRx or similar discount networks frequently offer modafinil at $40 to $60 per month in Illinois, sometimes lower for 90-day supplies. GoodRx is not a form of insurance and prices change daily, but it represents one of the most accessible immediate-discount tools for uninsured patients. Patients should present the discount card before the pharmacist rings the prescription, not after, because the transaction must be processed under the coupon rather than reversed.

The FDA's Office of Generic Drugs maintains data on approved modafinil generics. As of early 2026, more than a dozen manufacturers hold approved ANDAs (Abbreviated New Drug Applications) for modafinil tablets, which keeps generic competition active and prices relatively low. [5]

GoodRx coupons, NeedyMeds, and the manufacturer's own patient assistance program are the three main discount layers available to Illinois cash-pay patients. Each operates independently: stacking them in the same transaction is not possible, so patients should compare the final price under each program before choosing one.

Illinois Medicaid Coverage for Provigil

Illinois Medicaid (administered through Managed Medicaid plans under Illinois Health Connect and the various Medicaid Managed Care Organizations) covers modafinil with prior authorization. A prior authorization (PA) approval typically requires documentation of a qualifying diagnosis, most commonly narcolepsy confirmed by polysomnography plus multiple sleep latency testing, or obstructive sleep apnea with documented CPAP use and residual excessive daytime sleepiness.

The American Academy of Sleep Medicine (AASM) practice parameters state that modafinil is indicated for excessive sleepiness associated with narcolepsy and provides Level 1 evidence for that indication. [6] Illinois Medicaid PA reviewers generally follow AASM or similar evidence-based guidelines when evaluating requests.

Off-label use for cognitive enhancement or fatigue in conditions not listed in the FDA label is unlikely to meet PA criteria. Prescribers submitting PA requests for shift-work sleep disorder should document that the patient works a non-traditional schedule (nights or rotating shifts) and that sleep disruption impairs functioning, consistent with the FDA-labeled indication. [1]

PA approvals in Illinois Medicaid are typically granted for 12 months and require renewal. Appeals are available if the initial request is denied; Illinois Medicaid's Administrative Hearing process allows patients to contest denials within 10 days of receiving a denial notice. Clinicians should retain copies of sleep study results, treatment records, and any CPAP compliance data (typically defined as 4 hours per night on 70% of nights over a 30-day period) when submitting or appealing a PA.

Once approved, Illinois Medicaid enrollees pay a nominal copay, often $3 to $4 per prescription for generic modafinil, making it one of the most affordable access pathways for eligible patients. [7]

Which Private Insurance Plans Cover Provigil in Illinois?

Most Illinois commercial insurance plans, including those sold on the Illinois Health Insurance Marketplace under the ACA, cover generic modafinil on Tier 2 or Tier 3 of their formularies. Brand Provigil, when covered at all, typically lands on Tier 3 or Tier 4, resulting in copays ranging from $60 to $200 per month depending on plan design.

Employer-sponsored plans in Illinois vary more widely. Large self-insured employers using PBMs (Pharmacy Benefit Managers) like CVS Caremark, Express Scripts, or OptumRx set their own formulary tiers, and some exclude brand Provigil entirely in favor of generic modafinil step therapy. Step therapy requirements may require a patient to try and fail generic modafinil before brand coverage is authorized, which is straightforward for most prescribers to document given that brand and generic are bioequivalent. [5]

Illinois enacted a step therapy law (Illinois Senate Bill 1753, codified at 215 ILCS 5/356z.44) that allows patients to request a step therapy exception when a clinical reason exists to bypass the required trial drug. Prescribers can invoke this when a patient has a documented allergy, contraindication, or prior treatment failure. Exception requests must receive a response within 72 hours (24 hours for urgent cases) under Illinois law.

Medicare Part D plans covering Illinois beneficiaries place modafinil on varying tiers. In 2026, most Part D plans that include modafinil require a PA for quantities above 30 tablets per 30 days or for indications beyond the three FDA-approved sleep disorders. Illinois seniors on Medicare who are denied coverage should request a Coverage Determination, then an Independent Review Entity (IRE) appeal if the plan-level decision is unfavorable. [7]

Is Compounded Modafinil Legal in Illinois?

Yes. Compounded modafinil is available in Illinois through state-licensed 503A compounding pharmacies. 503A pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding for individual patient prescriptions when a licensed prescriber has a valid patient-prescriber relationship. [8]

Compounded modafinil is not FDA-approved and is not AB-rated equivalent to brand Provigil. The compounding pharmacy produces the preparation from bulk active pharmaceutical ingredient (API), and quality standards depend on the individual pharmacy's USP 795 compliance. Illinois requires 503A pharmacies to be licensed by the Illinois Department of Financial and Professional Regulation (IDFPR) and to comply with USP standards for non-sterile compounding. [9]

The FDA maintains a list of drug products that may not be compounded under Section 503A. As of the 2026 publication of this article, modafinil does not appear on the FDA's 503A Difficult to Compound or Essentially a Copy lists, meaning it remains permissible for 503A compounding when specific patient need is documented. [8]

Telehealth prescribers licensed in Illinois can legally prescribe compounded modafinil through a 503A pharmacy as long as the prescribing relationship meets Illinois requirements: the prescriber must hold an active Illinois license, a valid patient-provider relationship must exist (which telehealth visits satisfy under Illinois law post-2020 telehealth expansion), and the prescription must be for a specific identified patient. [10]

Pricing for compounded modafinil varies by pharmacy and formulation. Some 503A pharmacies partnered with telehealth platforms price compounded modafinil significantly below the $80-per-month retail generic average, in some cases at little to no out-of-pocket cost when bundled with a membership or subscription model. Patients should verify the pharmacy's IDFPR license status at idfpr.illinois.gov before filling any compounded prescription.

The HealthRX Illinois Modafinil Access Framework ranks the five access pathways by typical monthly out-of-pocket cost for a 200 mg daily dose in 2026:

1. Illinois Medicaid (with approved PA): $3 to $4 copay
2. Compounded modafinil via licensed 503A telehealth pharmacy: $0 to $40 (platform-dependent)
3. Generic modafinil with GoodRx or coupon at Illinois retail: $40 to $60
4. Generic modafinil cash at Illinois retail without coupon: $70 to $90
5. Brand Provigil on commercial insurance Tier 3: $60 to $200

Telehealth Prescribing of Provigil in Illinois

Illinois law permits telehealth prescribing of modafinil. The prescriber must hold an active Illinois license (or a temporary permit under the Illinois Telehealth Act for out-of-state providers in specific circumstances). Modafinil is a Schedule IV controlled substance, which means the prescriber must be registered with the DEA and comply with the Ryan Haight Act as amended. [2]

The Ryan Haight Act historically required an in-person evaluation before any telemedicine prescription for a controlled substance. The DEA's 2023 proposed telemedicine rules and subsequent Special Registration framework created pathways for telemedicine prescribing of Schedule III and IV substances, including modafinil, without an in-person visit when certain conditions are met. [11] Illinois-based patients using HealthRX or similar telehealth platforms can receive a modafinil evaluation and, if appropriate, a prescription through a fully online visit.

Sleep-related indications still require supporting documentation. A prescriber cannot diagnose narcolepsy over a video call alone. Patients will typically need to provide prior sleep study results or be referred for a home sleep test or polysomnography before a modafinil prescription for narcolepsy is appropriate. For shift-work sleep disorder, documentation of the work schedule and its impact on sleep may be sufficient.

The Illinois Telehealth Act (Public Act 101-0527) requires Illinois insurers to reimburse covered telehealth services at parity with in-person services. [10] That means the telehealth visit cost itself should not be a barrier for insured Illinois patients seeking a modafinil evaluation.

Discount Programs and Savings Cards for Modafinil in Illinois

Several discount mechanisms reduce out-of-pocket costs for Illinois patients who do not have adequate insurance coverage for modafinil.

GoodRx and similar PBM-bypass coupons. GoodRx, RxSaver, and Blink Health negotiate prices with pharmacy networks and pass the discount to patients via a card or app code. In Illinois, GoodRx prices for generic modafinil 200 mg (30 tablets) range from $28 to $65 depending on pharmacy. These programs cannot be combined with Medicaid or Medicare Part D, and using them for a Medicare-covered drug may constitute a coordination issue. Cash-pay patients have no such restriction.

NeedyMeds. NeedyMeds maintains a database of manufacturer patient assistance programs (PAPs). The brand Provigil patient assistance program, administered through Cephalon (now Teva Pharmaceuticals), provides free or reduced-cost brand medication to patients who meet income criteria, typically at or below 400% of the federal poverty level and without adequate insurance. [12] Applications require prescriber co-signature and income documentation.

Illinois Rx Buying Club (RXBC). Illinois operates a state-level prescription discount program through the Department of Healthcare and Family Services. While not insurance, it negotiates pharmacy rates and is available to Illinois residents regardless of income. Enrollment is free at Illinois.gov. Discounts on generic modafinil under this program range from 10% to 30% off retail.

Manufacturer copay cards. Teva Pharmaceuticals has periodically offered copay assistance for brand Provigil for commercially insured patients who do not have adequate tier coverage. These cards typically do not apply to government-funded insurance (Medicaid, Medicare, CHIP, TRICARE). Availability changes; patients should check Teva's patient support portal directly before counting on this option for 2026.

Clinical Evidence Supporting Modafinil Prescribing

Modafinil's approval rests on a well-characterized trial base. The 1998 US Modafinil in Narcolepsy Multicenter Study (N=271, Annals of Neurology) demonstrated that 200 mg and 400 mg doses each produced significant reductions in Epworth Sleepiness Scale scores and maintenance of wakefulness test improvements compared to placebo, with P<0.001 for the primary endpoints. [4] A subsequent trial published in the same journal (N=271 in the parallel-group arm) confirmed durability of effect over 40 weeks of continuous treatment. [4]

For obstructive sleep apnea, a randomized trial published in JAMA (Schwartz et al., 2003, N=157) showed that modafinil 200 mg daily significantly improved wakefulness in OSA patients already using CPAP but with residual sleepiness, with mean Epworth Sleepiness Scale reduction of 2.1 points vs. 0.3 for placebo (P<0.001). [13]

The FDA's full prescribing information for Provigil documents contraindications including known hypersensitivity to modafinil or armodafinil, and warns of serious rash (including Stevens-Johnson Syndrome), psychiatric symptoms (hallucinations, mania, suicidal ideation), and cardiovascular effects in patients with pre-existing conditions. [1] Illinois prescribers must review this label and conduct a cardiovascular history before prescribing.

Modafinil is a moderate inducer of CYP3A4 and may reduce plasma concentrations of hormonal contraceptives. [1] Illinois prescribers and pharmacists should counsel patients on the need for non-hormonal backup contraception or an alternative method while taking modafinil and for one month after stopping it. This interaction is particularly relevant for telehealth prescribers who may not have full medication reconciliation from a primary care record.

The American Academy of Sleep Medicine's Clinical Practice Guideline for the Treatment of Central Disorders of Hypersomnolence (2021) rates modafinil as a strong recommendation for narcolepsy type 1 and type 2, with a statement that "we recommend the use of modafinil for the treatment of EDS in patients with NT1 and NT2 (GRADE: strong; evidence quality: moderate)." [6]

How Illinois Patients Can Start a Modafinil Prescription in 2026

The pathway to a legal Illinois modafinil prescription follows a consistent sequence. The prescriber must establish the diagnosis, confirm the patient lacks contraindications, and then write a Schedule IV prescription that complies with DEA and Illinois requirements.

For narcolepsy, the diagnostic workup typically includes a polysomnogram followed by a multiple sleep latency test (MSLT), interpreted by a board-certified sleep medicine physician. [6] Results showing a mean sleep latency of 8 minutes or less on the MSLT, combined with two or more sleep-onset REM periods, support a narcolepsy diagnosis under ICSD-3 criteria published by the American Academy of Sleep Medicine. [6]

For shift-work sleep disorder, documentation of a non-traditional work schedule and a complaint of excessive sleepiness or insomnia linked to that schedule is the primary requirement. No polysomnography is mandatory for this indication under the FDA label. [1]

Telehealth platforms like HealthRX can conduct the clinical evaluation, review uploaded sleep study records, and, where appropriate, issue an Illinois-compliant Schedule IV prescription to an Illinois-licensed pharmacy or a licensed 503A compounding pharmacy. The typical turnaround from initial telehealth visit to prescription at an Illinois pharmacy is one to two business days.

Illinois Medicaid patients who pursue a telehealth evaluation should confirm that their Medicaid Managed Care Organization (MCO) covers the specific telehealth platform they use, since MCO networks vary. Illinois's five Medicaid MCOs (Aetna Better Health, BlueCross Community Health Plan, Centene/IlliniCare, Meridian Health Plan, and Molina Healthcare of Illinois) each maintain their own telehealth provider directories.

Patients whose PA is denied should request a peer-to-peer review, in which the prescribing clinician speaks directly with the insurance company's medical reviewer. Peer-to-peer reviews reverse denials in approximately 30% to 50% of cases in general, though data specific to modafinil PA denials in Illinois are not publicly reported. [14]

Generic modafinil 200 mg taken once each morning with or without food remains the standard starting dose per the FDA label, with the option to split to 100 mg in patients who experience side effects. [1]